Clinical uses of Cerebrolysin in Pediatric Neuropsychiatry

Aamir Jalal Al Mosawi

 

Advisor in Pediatrics and Pediatric Psychiatry Children Teaching Hospital of Baghdad Medical City,

Head, Iraq Headquarter of Copernicus Scientists International Panel Baghdad, Iraq

 

*Corresponding author: Al-Mosawi AJ, Advisor in Pediatrics and Pediatric Psychiatry Children Teaching Hospital of Baghdad Medical City, Head, Iraq Headquarter of Copernicus Scientists International Panel Baghdad, Iraq, Email: almosawiaj@yahoo.com

 

Citation: Al-Mosawi AJ (2020) Clinical uses of Cerebrolysin in Pediatric Neuropsychiatry. Sci World J Pharm Sci, 1(1);1-4

 

Copyright: © 2020, Al-Mosawi AJ, This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited

 

INTRODUCTION

In 1949, Austrian scientist Gerhart Harrer from the University of Innsbruck reported that the process of enzymatic hydrolysis of the brain tissue producing a protein-based liquid, cerebrolysin can stimulate nerve cells. Cerebrolysin which was probably first registered in Austria in 1954, and was also called (FPF1070) is a protein-based liquid mixture of free amino acids (85%) and 15% biologically active low molecular weight amino acid sequences which include low molecular weight neuro-peptides [1-5]

 

• Fulltext Article